Partnership establishes grant to advance immunology research in Canada
MARKHAM, ON, Oct. 8. 2015 /CNW/ - Canadian transplant researchers will receive an additional boost thanks to a new collaboration between Astellas Pharma Canada, Inc. (Astellas) and the Canadian Society of Transplantation (CST).
Astellas has committed $200,000 over a two-year period to launch the Astellas CST Clinical Research Grant Program. This program will support Canadian investigators in the field of transplantation through a peer-reviewed research grant competition, with the ultimate goal of improving long-term outcomes and quality of life for transplant recipients. The primary focus for the inaugural year will be clinical research in solid organ transplantation.
"Astellas is committed to providing important resources and programs that will help further research in solid organ transplantation," said Michael Tremblay, president, Astellas Pharma Canada. "We are proud to partner with the Canadian Society of Transplantation and provide funding in support of its efforts to achieve better patient outcomes."
"The mission of the Canadian Society of Transplantation is to foster research, support professional development and advance patient care in solid organ transplantation, " said Dr. Steven Paraskevas, President of the CST. "It is with great pride that the CST announces this exciting program, made possible by our partnership with Astellas Pharma Canada. This grant adds a new dimension to the opportunities available to our members, and the transplant community."
The application deadline for the Astellas CST Clinical Research Grant Program is January 31, 2016. For more information about the application process and eligibility criteria, please visit www.cst-transplant.ca or www.astellas.ca.
About the Canadian Society of Transplantation
The Canadian Society of Transplantation is the professional organization for physicians, surgeons, scientists and allied health professionals working in the field of transplantation. Its mission is to advance the practice and science of transplantation for the benefit of Canadians and society by leading, advancing, and advocating for patient care, research, and education in donation and transplantation in Canada. More information about the CST can found at www.cst-transplant.ca/.
About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.
For more information, please visit our website at www.astellas.com/en.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. In Canada, Astellas has an intense commercial focus on five therapeutic areas – Urology, Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE Astellas Pharma Canada, Inc.
For further information: Rob Gallaher, Canadian Society of Transplantation, 1 (877) 968-9449, firstname.lastname@example.org; Michelle Reale, Corporate Communications, Astellas Pharma Canada, Inc., (905) 946-5621, email@example.com